BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts.

On September 23, 2025, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) hit a 52-week low, falling 23.7% over the past year to $52.93. Despite this decline, the company maintains an 81.8% gross profit margin and trades at an attractive P/E ratio relative to its growth potential.

Earlier this month, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced positive Phase 3 data for its PALYNZIQ® therapy in teens with phenylketonuria, showing significant reductions in dangerous phenylalanine levels compared to diet alone. While increased competition and shifting biotech dynamics have pressured the stock, strong clinical results and its low valuation suggest potential upside if pipeline assets succeed.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes treatments for rare, life-threatening diseases across the U.S., Europe, Latin America, the Middle East, Asia Pacific, and other international markets. It is one of the Best Widow and Orphan Stocks.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.

Disclosure: None.